A 24-year follow-up study in PCa showed that the use of cholesterol-lowering statins lowers the incidence of lethal PCa in PTEN-null cancers and enriches TCR signaling genes in normal tumor-adjacent prostate tissue, opening up a rationale for studying statins as immune modulators in PCa.144. The gene discussed is PTEN; the disease is neoplasm.